AC Immune (NASDAQ:ACIU) Short Interest Up 94.4% in December

AC Immune (NASDAQ:ACIU) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 3,593,227 shares, a growth of 94.4% from the November 30th total of 1,848,164 shares. Approximately 3.8% of the shares of the stock are sold short. Based on an average daily volume of 2,209,361 shares, the short-interest ratio is presently 1.6 days. Based on an average daily volume of 2,209,361 shares, the short-interest ratio is presently 1.6 days. Approximately 3.8% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, October 8th. Zacks Research upgraded shares of AC Immune from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Hedge Funds Weigh In On AC Immune

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC purchased a new position in AC Immune during the third quarter worth approximately $48,000. Susquehanna International Group LLP acquired a new stake in shares of AC Immune during the 3rd quarter worth $63,000. Sei Investments Co. acquired a new stake in shares of AC Immune during the 2nd quarter worth $51,000. Acadian Asset Management LLC raised its position in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in AC Immune in the third quarter valued at $549,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $3.13 on Friday. The company has a market cap of $314.28 million, a P/E ratio of -3.73 and a beta of 1.60. The business has a fifty day simple moving average of $3.10 and a 200-day simple moving average of $2.62. AC Immune has a 52 week low of $1.43 and a 52 week high of $4.00.

AC Immune (NASDAQ:ACIU) last released its earnings results on Tuesday, November 4th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $0.81 million. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%. Sell-side analysts expect that AC Immune will post -0.62 earnings per share for the current fiscal year.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.